Lenalidomide Plus Rituximab (R) in Non Follicular NHL

Exclusion Criteria

• •Previously untreated patients
• •Patients with diagnosis of typical Chronic Lymphocytic Leukemia (CLL)
• •Women and men not agreeing to take adequate contraceptive precautions during and for at least 4 weeks after cessation of therapy
• •Pregnant or lactating women
• •History of other malignancies within 3 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer, low grade, early stage localized prostate cancer treated surgically with curative intent, good prognosis ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone with curative intent
• •Active bacterial, viral or fungal infection requiring systemic therapy
• •Concurrent co-morbid medical condition which might exclude administration of therapy
• •Cardiac insufficiency (NYHA grade III/IV)
• •Myocardial infarction within 6 months of entry on the study
• •Severe chronic obstructive pulmonary disease with hypoxemia
• •Severe diabetes mellitus difficult to control with adequate insulin therapy
• •Hypertension that is difficult to control
• •Creatinine clearance \< 30 mL/min calculated by Cockcroft-Gault estimation
• •Absolute neutrophil count (ANC) \<= 1 x 109/L, unless due to lymphoma involvement and not responding to 5 days of Granulocyte colony-stimulating factor (G-CFS) treatment
• •Platelets count \<=75.000/mm3, unless due to lymphoma involvement
• •HIV and Hepatitis B virus (HBV) positivity
• •Hepatitis C virus (HCV) positivity in presence of high level of virus replication and Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) \> x 2.5 ULN
• •Central nervous system (CNS) involvement by lymphoma
• •Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins
• •Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent